drugset / Trial / NCT04073537
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Timeline
- Start
- 2019-10-31
- Primary completion
- 2021-07-31
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |